Late-Relapsing Hepatitis after Yellow Fever.
emerging virus
flavivirus
hepatitis
liver biopsy
liver damage
persistent infection
relapsing hepatitis
viral persistence
yellow fever
yellow fever virus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
17 02 2020
17 02 2020
Historique:
received:
21
12
2019
revised:
30
01
2020
accepted:
07
02
2020
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
20
2
2021
Statut:
epublish
Résumé
One patient presented hyporexia, asthenia, adynamia, and jaundice two months after acute yellow fever (YF) onset; plus laboratory tests indicating hepatic cytolysis and a rebound of alanine and aspartate transaminases, and total and direct bilirubin levels. Laboratory tests discarded autoimmune hepatitis, inflammatory or metabolic liver disease, and new infections caused by hepatotropic agents. Anti-YFV IgM, IgG and neutralizing antibodies were detected in different times, but no viremia. A liver biopsy was collected three months after YF onset and tested positive for YFV antigens and wild-type YFV-RNA (364 RNA-copies/gram/liver). Transaminases and bilirubin levels remained elevated for five months, and the arresting of symptoms persisted for six months after the acute YF onset. Several serum chemokines, cytokines, and growth factors were measured. A similar immune response profile was observed in the earlier phases of the disease, followed by more pronounced changes in the later stages, when transaminases levels returned to normal. The results indicated viral persistence in the liver and continual liver cell damage three months after YF onset and reinforced the need for extended follow-ups of YF patients. Further studies to investigate the role of possible viral persistence and the immune response causing relapsing hepatitis following YF are also necessary.
Identifiants
pubmed: 32079143
pii: v12020222
doi: 10.3390/v12020222
pmc: PMC7077229
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Cytokines
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Infect Dis. 2019 Jul;19(7):750-758
pubmed: 31104909
Lancet Infect Dis. 2001 Aug;1(1):11-20
pubmed: 11871403
Virol J. 2013 Feb 14;10:58
pubmed: 23410000
BMC Infect Dis. 2015 Nov 02;15:493
pubmed: 26527283
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2311
pubmed: 23875046
J Clin Microbiol. 2018 Sep 25;56(10):
pubmed: 30021822
Bull World Health Organ. 1972;46(5):659-67
pubmed: 4538039
Indian J Med Res. 2009 Mar;129(3):335-7; author reply 337
pubmed: 19491431
Bull World Health Organ. 1970;42(1):95-102
pubmed: 5309915
Emerg Infect Dis. 2019 Jun;25(6):1248-1249
pubmed: 30870138
J Clin Microbiol. 2012 Dec;50(12):4054-60
pubmed: 23052311
Vaccine. 2016 Mar 4;34(10):1247-51
pubmed: 26845742
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904